CareDx (CDNA)
(Real Time Quote from BATS)
$13.50 USD
-0.69 (-4.86%)
Updated Jun 17, 2024 03:32 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
CDNA 13.50 -0.69(-4.86%)
Will CDNA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CDNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CDNA
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
CDNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
How CareDx (CDNA) Stock Stands Out in a Strong Industry
Other News for CDNA
Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Dexcom (DXCM) and CareDx (CDNA)
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
CareDx (CDNA) Gets a Hold from H.C. Wainwright
Decoding 6 Analyst Evaluations For CareDx
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress